Bayer Wins EU Approval for Lynkuet to Treat Menopausal and Breast Cancer Therapy Hot Flashes
Bayer AG has received EU approval for Lynkuet™ (elinzanetant), a hormone-free therapy for treating moderate to severe vasomotor symptoms (VMS) like hot flashes associated with menopause or breast cancer therapy. The approval follows positive results from the OASIS Phase III clinical program, showing significant reduction in VMS frequency and severity with a favorable safety profile. Lynkuet™ offers a new treatment option for affected women.
Bayer AG has received marketing authorization from the European Commission for Lynkuet™ (elinzanetant), a dual neurokinin (NK-1 and NK-3) receptor antagonist. This hormone-free therapy is approved in the EU for the treatment of moderate to severe vasomotor symptoms (VMS), such as hot flashes, associated with menopause or caused by adjuvant endocrine therapy for breast cancer. The approval is based on positive results from the OASIS Phase III clinical program, which demonstrated significant reduction in the frequency and severity of VMS and a favorable safety profile. Lynkuet™ now offers a new treatment option for women affected by these symptoms. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on November 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
